The underutilization of medications for alcohol use disorders is a sensible choice

Published:August 01, 2022DOI:
      Dear Editor,


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Antonelli M.
        • Sestito L.
        • Tarli C.
        • Addolorato G.
        Perspectives on the pharmacological management of alcohol use disorder: are the approved medications effective?.
        Eur J Intern Med. 2022; (Online May 18)
        • Braillon A.
        Nalmefene in alcohol misuse: junk evaluation by the European medicines agency.
        BMJ. 2014; 348: g2017
        • Palpacuer C.
        • Laviolle B.
        • Boussageon R.
        • Reymann J.M.
        • Bellissant E.
        • Naudet F.
        Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials.
        PLOS Med. 2015; 12e1001924
        • Naudet F.
        Comparing nalmefene and naltrexone in alcohol dependence: is there a spin?.
        Pharmacopsychiatry. 2016; 49: 260-261
        • Naudet F.
        • Palpacuer C.
        • Boussageon R.
        • Laviolle B.
        Evaluation in alcohol use disorders - insights from the nalmefene experience.
        BMC Med. 2016; 14: 119
        • Palpacuer C.
        • Hammas K.
        • Duprez R.
        • Laviolle B.
        • Ioannidis J.P.A.
        • Naudet F
        Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
        BMC Med. 2019; 17: 174
        • Braillon A.
        • Naudet F.
        • Cristea I.A.
        • Lexchin J
        Baclofen and alcohol use disorders: breakthrough or great white Elephant?.
        Alcohol Alcohol. 2020; 55: 49-50
        • Naudet F.
        • Braillon A.
        • Cristea I.A.
        • Lexchin J.
        Restoring the Bacloville trial: efficacy and harms.
        Addiction. 2020; 115: 2184-2186
        • Chaignot C.
        • Zureik M.
        • Rey G.
        • Dray-Spira R.
        • Coste J.
        • Weill A.
        Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
        Pharmacoepidemiol Drug Saf. 2018; 27: 1239-1248
      1. Haute Autorité de Santé. BACLOCUR (baclofène). 11 December 2019. Available at Accessed 9 July 2022.

        • Munkholm K.
        • Paludan-Müller A.S.
        • Boesen K.
        Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis.
        BMJ Open. 2019; 9e024886
        • Leichsenring F.
        • Steinert C.
        • Rabung S.
        • Ioannidis J.P.A.
        The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.
        World Psychiatry. 2022; 21: 133-145
        • Chick J.
        Unhelpful prescribing in alcohol use disorder: risk and averting risk.
        Alcohol Alcohol. 2019; 54: 1-4